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Abstract
Objective Multimodality treatments are effective for locally advanced non-small cell lung cancer (LA-NSCLC) showing 
benefits in overall (OS) and disease-free survival (DFS), but these options are frequently denied to elderly patients.
Methods The objectives of this retrospective study were: to investigate mortality, morbidity and oncological outcomes 
of pulmonary resection after induction therapy (IT) for NSCLC in elderly patients. We divided the cohort into two: 
patients < 70 years (group A) and patients ≥70 years (group B). A multivariable logistic regression was built to identify 
factors associated with morbidity.
Results 77 patients underwent pulmonary resection after IT, 27 were aged ≥70 years. Type of chemotherapy, surgical 
procedures, pathological stages were comparable between the two groups, while the preoperative use of chemo-radiation 
therapy regimen was more frequent in group A (p = 0.027). In-hospital mortality was similar, while the percentage of patients 
with complications (38% vs 48.1%, p = 0.47) and the complication rate (50% vs 77%, p = 0.01) were higher in group B, but 
the severity of complications was comparable. The multivariable analysis did not identify any risk factors associated with 
morbidity. OS at 3 years and DFS at 2 years were not different (61% vs 48.5%, p = 0.64; 61.7% vs 44%, p = 0.393).
Conclusions Lung resection for LA-NSCLC after IT can be performed safely in selected elderly patients with favourable 
postoperative and mid-term oncological results.
Keywords NSCLC multimodal treatment · Neoadjuvant therapy · Elderly · Locally-advanced NSCLC · Survival
Introduction
The geriatric population is increasing worldwide and lung 
cancer is frequently diagnosed in elderly patients represent-
ing a leading cause of death. Age per se has been shown to 
be an important risk factor for morbidity and mortality after 
lung resection for non-small cell lung cancer (NSCLC) [1–6] 
and also the incidence of other diseases is more frequent in 
the older population then the association between these two 
conditions could preclude a complete oncological treatment.
Multimodality treatments have demonstrated clinical ben-
efits in terms of overall and disease-free survival for locally 
advanced NSCLC (LA-NSCLC) [7–12]. Induction therapy 
(IT) has demonstrated some advantages: potential attack to 
micrometastases, improved systemic drug delivery and tol-
erability, better compliance with subsequent therapies, and 
also allows more time to identify unsuspected metastases or 
comorbidities contraindicating a definitive treatment as sur-
gery [13]. The geriatric population is often underrepresented 
or excluded from clinical trials for the fear of higher toxicity 
and comorbidities and therefore there is a lack of specific 
data on therapeutic multimodal strategies in this population 
[1, 2, 7]. Some studies demonstrated higher toxicity and less 
benefits in the elderly subgroup [14], other confirmed the 
feasibility and efficacy of combined treatments [15].
The aim of our retrospective study was to analyze mor-
tality and morbidity of lung resection after IT in patients 
70 years or older identifying the presence of independent 
risk factors of postoperative complications. Furthermore, we 
 * Alberto Salvicchi 
 alberto.salvicchi@libero.it
1 Thoracic Surgery Unit, Careggi University Hospital, Largo 
Brambilla, 1, 50134 Florence, Italy
2 Medical Oncology Unit, Careggi University Hospital, 
Florence, Italy
3 Respiratory Medicine, Careggi University Hospital, Florence, 
Italy
 General Thoracic and Cardiovascular Surgery
1 3
examined also the oncological short and mid-term results 
to evaluate the feasibility and oncological adequacy of the 
multimodal treatment on the elderly.
Materials and methods
From June 2014 to December 2018, we retrospectively 
reviewed the medical records of all patients who received 
preoperative chemotherapy with or without radiation ther-
apy and subsequently lung resection at Careggi University 
Hospital, Florence. Our institutional review board granted 
approval and waived the requirement for specific informed 
consent for this retrospective study.
Baseline and postoperative variables included demo-
graphics, comorbidities, pulmonary cardiovascular and renal 
assessment, preoperative clinical stage, pathological stage, 
hospital length of stay, duration of chest tubes, complica-
tions, and peri-operative mortality (between 30 days).
Clinical stage was assessed with whole-body computer 
tomographic scan (wb-CT), positron emission tomographic 
scan (PET-CT-scan), bronchoscopy, endobronchial or esoph-
ageal ultrasound (EBUS/EUS) and video-mediastinoscopy. 
Clinical and pathological stages were resumed with the 
American Joint Committee on Cancer  8th Edition TNM 
Classification [16]. Stages obtained before the publication 
of the 8th Edition were re-checked and reported by the first 
author (B.S.).
All patients with LA-NSCLC were evaluated by the insti-
tutional Multidisciplinary Tumour Board (MTB) composed 
by expert oncologists, pulmonologists, radio-therapists, 
thoracic surgeons, and dedicated thoracic radiologists. At 
the weekly meeting, the individual treatment was decided 
based on the clinical stage and the most recent international 
guidelines [17, 18]. In the absence of progression of dis-
ease at the re-staging assessment, including CT-scan and 
PET-CT-scan, patients were referred to thoracic surgery and 
dedicated anaesthesiology service to evaluate the operability.
During the study period, we compared all patients who 
underwent IT followed by radical surgery for LA-NSCLC 
dividing the population based on the age at the begin-
ning of the treatment: the Group A consisted of patients 
aged < 70 years while in the Group B were included patient 
aged ≥70 years. The assignment of 70 years as a threshold to 
define elderly patients was arbitrary but is frequently used in 
the literature [19, 20]. Follow-up was assessed by outpatient 
visits including interval medical history, physical examina-
tion, and enhanced contrast wb-CT scan every 6 months.
Statistical analysis
Statistical analysis was performed using SPSS 24.0 soft-
ware (SPSS Inc., Chicago, IL). Continuous variables are 
expressed as median, mean values ± SD and compared with 
unpaired t-test or non-parametric Mann–Whitney test, if not 
normally distributed. Categorical variables were analyzed 
using the χ2 test. Univariate and a multivariable logistic 
regression analysis were built to identify preoperative fac-
tors associated with overall morbidity, including a set of 
variables chosen on clinical relevance and entered in the 
multivariable model if p < 0.20 (age, sex, Eastern Coopera-
tive Oncology Group Performance Status (ECOG PS) [21], 
American Society of Anesthesiologists (ASA) score, Charl-
son Comorbidity Index (CCI) [22], number of comorbidi-
ties, pneumonectomy, chest wall resection, VATS approach, 
FEV1% < 70).
The Kaplan–Meier method was used to calculate overall 
and disease-free survival. Overall survival (OS) was calcu-
lated from the date of the beginning of treatments to death 
or date of the last follow-up (31th December 2018); disease-
free survival (DFS) was calculated for those patients who 
received a radical resection from the date of operation to 
the date of the first evidence of recurrence. Differences in 
overall and disease-free survival between age classes were 
determined by log-rank analysis. Statistical significance for 
all tests was set at a probability value of less than 0.05.
Results
During the study period, we identified 77 patients who 
underwent IT and consequently lung resection with system-
atic lymph node dissection.
Table 1 shows the preoperative characteristics, comor-
bidities, clinical-stage, type of induction treatment, thera-
peutic regimens, clinical response, surgical procedure, and 
pathological stage of the two groups. ECOG PS was worse 
for the elderly patient (p =  < 0.01). Although the number 
and type of comorbidities were not different between the two 
groups, the CCI was statistically higher for patients of Group 
B (p = 0.03). Adenocarcinoma was more frequent in group 
A (62% vs 40.7%), but this difference was not significant. 
The majority of patients were classified as clinical stage IIIA 
in both groups. The use of cisplatin-based chemotherapy 
regimen (CDDP) was more frequent in group A without sta-
tistical significance (80% vs 66.7%, p = 0.24). However, in 
Group A, a large portion of patients underwent to combined 
preoperative chemo-radiation therapy regimen (p = 0.027). 
Regarding the surgical procedure, we had similar percent-
ages of lobectomy, sleeve lobectomy, and pneumonectomy, 
but we noted a higher number of patients of Group A who 
underwent chest wall resection (20% vs 11.1%, p = 0.52).
The pathological stage did not differ between the two 
groups and we had a total of 10 (12.9%) complete responses 
after IT.
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Table 1  Demographic, 
preoperative, oncological, and 
surgical characteristics of the 
population study divided into 
the two groups
Variables Patients < 70 n = 50 Patients > 70 n = 27 p
Median age 62.5 (35–69) 73 (70–79)  < 0.01
Males 29 (58%) 19 (70.4%) 0.33
ASA score  < 0.01
 1 16 (32%) 0
 2 12 (24%) 13 (48.1%)
 3 22 (44%) 14 (51.9%)
ECOG PS score  < 0.01
 0 34 (68%%) 10 (37%)
 1 12 (24%) 16 (59.3%)
 2 4 (8%) 1 (3.7%)
CCI 0.03
 0 21 (42%) 9 (33.3%)
 1 7 (14%) 12 (44.4%)
 2 13 (26%) 3 (11.1%)
 3 8 (16%) 2 (7.4%)
 4 0 1 (3.7%)
 5 1 (2%) 0
Mean FEV1% 82.96 ± 18.39 83.88 ± 23.19 0.88
Mean DLCO% 66.55 ± 15.43 68 ± 18.83 0.79
Creatinine mg/dl 0.93 ± 0.19 0.9 ± 0.21 0.68
Hb gr/dl 12.14 ± 1.02 11.85 ± 2.16 0.63
RBC 3.91 ± 0.45 3.99 ± 0.65 0.67
WBC 8015 ± 2998 8649 ± 5307 0.66
Number of comorbidities 0.35
 0 14 (28%) 5 (18.5%)
 1 13 (26%) 5 (18.5%)
 2 10 (20%) 9 (33.3%)
 > 3 13 (26%) 8 (29.6%)
Comorbidities 0.57
 Hypertension 11 (25%) 13 (50%)
 COPD 15 (34%) 9 (34.6%)
 DM 8 (18%) 3 (11.5%)
 Peripheral vascular disease 3 (6.8%) 2 (7.6%)
CAD 2 (4.5%) 2 (7.6%)
 Other tumours 3 (6.8%) 5 (19.2%)
Pathology 0.03
 ADC 31 (62%) 11 (40.7%)
 SCC 12 (24%) 15 (55.6%)
 NSCLC NOS 2 (4%) 0
 Other 5 (10%) 1 (3.7%)
Clinical stage 0.72
 Ib 1 (2%) 0
 IIb 3 (6%) 1 (3.7%)
 IIIa 35 (70%) 22 (81.5%)
 IIIb 10 (20%) 3 (11.1%)
 IV 1 (2%) 1 (3.7%)
 CHT 38 (76%) 26 (96.3%) 0.027
  CHT + RT 12 (24%) 1 (3.7%)
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The mortality rate (2% vs 0%), the proportion of patients 
who suffered from any complication (38% vs 48.1%), 
median ICU stay (1 vs 1 day) and median length of stay (7 
vs 8.5 days) were not statistically different between the two 
groups (p = 0.45; p = 0.47; p = 0.5 and 0.49 respectively). 
The overall complication rate was higher in group B (50% 
vs 77%) and in particular we observed a significantly higher 
incidence of atrial fibrillation (4% vs 25.9%; p < 0.01). The 
grade of complications, measured with the Clavien-Dindo 
classification [23], was not different between the two groups 
(Table 2).
The ECOG PS score ≥1 and chest wall resection were 
risk factors associated with complications at univariate 
analysis (OR 2.57 p = 0.047 and OR 4.011 p = 0.034 respec-
tively). Despite the presence of some high OR values, the 
multivariable analysis demonstrated the absence of any sig-
nificant factor associated with overall morbidity (Table 3). 
The minimally-invasive VATS approach showed a favour-
able association with complications in both univariate and 
multivariable analyses (OR 0.167, p = 0.023).
At the median follow-up of 22 months (4–54 months), 52 
(67.5%) patients were alive and the OS at 3 years (Fig. 1) and 
ASA American Society of Anesthesiologists, ECOG PS Eastern Cooperative Oncology Group Performance 
Status, CCI Charlson Comorbidity Index; FEV1% Forced Expiratory Volume in 1  s, DLCO% Diffusing 
Capacity of the Lung for Carbon Monoxide, RBC red blood cells, WBC white blood cells, COPD chronic 
obstructive pulmonary disease, DM diabetes mellitus, CAD coronary artery disease, ADC adenocarcinoma, 
SCC squamous cell carcinoma, NOS not otherwise specified, CHT chemotherapy, CHT + RT chemother-
apy + radiotherapy, CDDP cisplatin-based chemotherapy, CBDCA carboplatin-based chemotherapy, VATS 
video-assisted thoracoscopic surgery, CR complete response
Table 1  (continued) Variables Patients < 70 n = 50 Patients > 70 n = 27 p
Type of chemotherapy 0.24
 Cddp 40 (80%) 18 (66.7%)
 Cbdca 7 (14%) 8 (29.6%)
 Other 3 (6%) 1 (3.7%)
Response to therapy 0.48
 Complete response 6 (12%) 3 (11.1%)
 Partial response 42 (84%) 21 (77.8%)
 Stable disease 2 (4%) 3 (11.1%)
Surgical procedure 0.82
 Pneumonectomy 7 (14%) 5 (18.5%)
 Bilobectomy 4 (8%) 1 (3.7%)
 Sleeve-lobectomy 7 (14%) 5 (18.5%)
 Lobectomy 28 (56%) 15 (55.6%)
 Segmentectomy 2 (4%) 1 (3.7%)
 Wedge resection 2 (4%) 0
Side 0.077
 Right 36 (72%) 14 (51.9%)
 Left 14 (28%) 13 (48.1%)
Side of pneumonectomy 0.82
 Right 5 (10%) 4 (14.8%)
 Left 2 (4%) 1 (3.7%)
VATS approach 8 (16%) 3 (11.1%) 0.73
Chest wall resection 10 (20%) 3 (11.1%) 0.52
Pathological stage 0.21
 CR 7 (14%) 3 (11.1%)
 Ia 7 (14%) 3 (11.1%)
 Ib 5 (10%) 2 (7.4%)
 IIa 1 (2%) 3 (11.1%)
 IIb 15 (30%) 5 (18.5%)
 IIIa 15 (30%) 8 (29.6%)
 IIIb 0 2 (7.4%)
 IVa 0 1 (3.7%)
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DFS at 2 years (Fig. 2) were not different between the two 
groups (61% vs 48.5%, p = 0.64; 61.7% vs 44%, p = 0.393). 
The elderly group has a median OS and DFS of 22 months 
and 10 months, respectively, while in the Group A OS and 
DFS were 22.5 and 9.5 months. Excluding postoperative 
death (n = 1), 20 patients (83.3%) died for cancer relapse. 
We observed 24 (49%) cancer recurrence in Group A and 14 
(51,9%) in Group B (p = 1): distant metastasis developed in 
14 (58.3%) and 9 (64.2%) patients, respectively.
Discussion
This retrospective study compared postoperative and mid-
term oncological outcomes of elderly patients, defined as 
patients aged > 70 years, versus younger treated by a multi-
modality approach including surgery for LA-NSCLC. Our 
results demonstrated that IT in a selected cohort of elderly 
patients was not associated with increased postoperative 
mortality.
The overall complication rate was still higher for the 
elderly who often suffered from some post-operative com-
plications, but non-life-threatening complications. The 
incidence of respiratory failure, pulmonary infections, or 
broncho-pleural fistula, the most frequent causes of disabil-
ity, and associated with post-operative death, were low and 
similar between the two groups. Furthermore, the grade of 
overall complication, resumed with the Clavien–Dindo clas-
sification, was no different between the two groups, and also 
the majority of patients suffered from grade 2 complications 
(26% vs 33%) that we can consider as minor complications.
Although the univariate analysis demonstrated that chest 
wall resection and ECOG PS [21] higher than 1 were risk 
factors for overall morbidity, the multivariable analysis did 
not confirm these findings. Therefore, our outcomes clearly 
showed that older age per se is not a risk factor for morbidity 
neither on univariate and multivariable analysis.
To date, there are few published papers focused on sur-
gical resection after IT in the geriatric population. Rivera 
et al. [1] conducted a match-analysis on data from a national 
database comparing the post-operative course of 81 elderly 
patients (defined as > 75  years or older) with younger 
patients. Although the mortality was similar, the authors 
reported a significantly increased incidence of postopera-
tive major complications (22.2% vs 14.8%, p = 0.03) and 
longer length of stay for elderly patients (14.9 vs 12 days, 
p =  < 0.01). The overall complication rate was 50% (minor 
complication n = 23 + major complication n = 18) abso-
lutely comparable with our findings. According to the 
Table 2  Post-operative 
outcomes
ICU intensive care unit
Characteristics Patients < 70 n = 50 Patients > 70 n = 27 p
In-hospital mortality 1 (2%) 0 0.45
ICU stay (days), median and range 1 (1–30) 1 (1–160) 0.5
Length of stay (days), median and range 7 (3–35) 8.5 (4–180) 0.49
Patients with at least one complication 19 (38%) 13 (48.1%) 0.47
Complication rate 25/50 (50%) 21/27 (77%) 0.01
Grade of complications (Clavien–Dindo) 0.6
 2 13 (26%) 9 (33.3%)
 3a 2 (4%) 2 (7.4%)
 3b 0 0
 4a 3 (6%) 1 (3.7%)
 4b 0 1 (3.7%)
 5 1 (2%) 0
Complications in detail
 Respiratory failure 7 (14%) 3 (11.1%) 0.71
 Atrial fibrillation 2 (4%) 7 (25.9%) < 0.01
 Prolonged air leak 3 (6%) 1 (3.7%) 0.5
 Chylothorax 2 (4%) 0 0.29
 Pneumonia and sputum retention 4 (8%) 3 (11.1%) 0.64
 Bleeding requiring blood transfusion 4 (8%) 5 (18.5%) 0.17
 Contralateral pneumothorax 2 (4%) 0 0.29
 Renal failure requiring dialysis 0 1 (3.7%) 0.17
 Broncho-pleural fistula 0 1 (3.7%) 0.17
 Subclavian vein thrombosis 1 (2%) 0 0.45
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authors, surgical resection after IT should be proposed to 
elderly patients considering that post-operative morbidity 
could be substantial. Another paper by Marquez-Medina [3] 
compared the post-operative results of a historical cohort 
of patients who underwent to definitive treatment of LA-
NSCLC including surgery and radiation therapy, demon-
strating no difference in postoperative mortality. The same 
outcomes were described by Coate et al. [7]. Yang et al. [2] 
observed no difference in 30-day or 90-day mortality, but 
an increased incidence of perioperative respiratory failure 
in patients older than 70. Moreover, even in our study, the 
multivariable analysis did not demonstrate age as a risk fac-
tor for postoperative complications. Although the outcomes Ta
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of all these papers are encouraging, we must consider that 
all were retrospective historical studies with a long study 
period and also were biased by the relatively small popula-
tion study, and lastly the definition of the elderly was het-
erogeneous between the studies.
The last evidence suggests that a bimodality approach 
(chemotherapy + radiation therapy VS chemotherapy + sur-
gery) has not been shown to be superior to another in terms 
of overall survival in patients with clinical mediastinal 
N2 involvement [12, 13]. A non-significant advantage in 
disease-free survival was described in the Intergroup 0139 
trial [15] in patients treated with the trimodality approach 
(chemotherapy + radiation therapy + surgery) compared with 
the bimodality treatment. Although in the cited randomized 
controlled trial elderly patients were not excluded, the geri-
atric population was underrepresented, and therefore few 
retrospective studies focused on the multimodality treatment 
in the elderly. Also in our population, radiation therapy was 
frequently administered to younger patients (24% vs 3.7%, 
p = 0.027) because this regimen is considered more aggres-
sive and it could be not-well tolerated for elderly patients 
who often had fragile stability and some co-morbid condi-
tions. Although not so much used in the whole study popula-
tion, the preoperative radiation therapy did not have a strong 
impact on postoperative complications as showed at univari-
ate analysis (Table 3).
Coate and coll [7] did not observe any overall statisti-
cally significant difference in survival between elderly and 
younger patients treated with curative intent. The same 
results were described by Yang [2] who also noted the 
absence of difference in the disease-free survival at univari-
ate and multivariable analysis. Our series had a relatively 
short study period, but we had encouraging oncological 
results as shown by a median OS and DFS of 22 months and 
10 months in both groups. Furthermore, the leading cause of 
death in both groups was recurrence and progression of can-
cer, not other comorbid conditions or diseases. These results 
demonstrate that age per se is not a contraindication for a 
curative-intent multimodality treatment and so this treatment 
could be proposed to a selected elderly population.
Our results and also data from the literature demonstrated 
that IT followed by major pulmonary resection for LA-
NSCLC is a feasible approach in the elderly, but none had 
shown an algorithm to correctly select the patient to mini-
mize the development of complications. The LA-NSCLC 
stage is a clinical scenario very heterogeneous and also the 
individual status of the elderly patient could be extremely 
variable and then only an individualized and tailored com-
prehensive evaluation could lead to the right selection. Sev-
eral scores are available to assess the elderly status, but the 
personal and individual judgment is still basilar in this mul-
tidisciplinary setting.
Furthermore, it is very important to adopt a more surgical 
conservative attitude: first of all, avoiding pneumonectomy 
and being less invasive using for example the thoracoscopic 
approach. Some papers have demonstrated the oncological 
adequacy, safety, and effectiveness of the thoracoscopic 
approach even after IT [24, 25].
Our study has some limitations: (1) is a single institution 
series, retrospectively analyzed between a short period with 
a study population of patients who underwent only surgery 
as definitive treatment; (2) the patient cohort is heterogene-
ous for the presence of patients affected by superior sulcus 
tumor or by patients with chest wall involvement; (3) we did 
not perform a comparison with definitive radiation therapy; 
(4) lastly there is a lack of a structured follow-up investiga-
tion about daily activity level and quality of life. However, 
the short study period (2014–2018) could be interpreted as 
an advantage for the use of all the modern techniques of 
staging and re-staging (mostly the restaging with PET-CT 
and EBUS-EUS), for the adoption of modern surgical and 
anaesthetic approaches and also for the latest therapeutic 
protocols in both neoadjuvant and adjuvant settings.
Conclusion
In conclusion, the multimodality approach for LA-NSCLC 
could be applied to the geriatric population because age per 
se is not a risk factor for postoperative mortality and mor-
bidity. Moreover, IT followed by surgery is a well-tolerated 
approach not associated with life-threatening postoperative 
complications, also in the elderly. More mid and long-term 
studies are necessary to investigate the oncological value of 
the multimodal approach in this population.
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